(800) 913-2022 | CONTACT PRODUCT FINDER

Join us in Minneapolis!

AMLI 2025
August 14-17, 2025 Minneapolis, MN

Clinical Presentation and Diagnosis of Autoimmune Blistering Disease
Breakfast Session • Friday, August 15, 2025 • 7:00AM - 8:00AM • Hyatt Regency Minneapolis

SPEAKER: Animesh Sinha, MD, PHD
Professor Department of Dermatology University at Buffalo

Join us in Chicago!

ADLM • July 28-31, 2025 Chicago, Illinois
BOOTH #725

EUROIMMUN Your Trusted Partner With A Bold New Look

Evolving Our Brand – Not Your Experience

FDA approval of the
NEW AP2400 in the US

Discover a new era of automated
T-SPOT.TB testing

Pattern IQ

IFA Training Program

Stop complicating
free testosterone
measurements

LEARN MORE

Euroimmun US Product Portfolio

Euroimmun US is one of the leading manufacturers worldwide and stands for innovation.

For further product information, please visit our Euroimmun US products page

Latest from Euroimmun US

July 29, 2025

Euroimmun Unveils New Visual Identity at ADLM 2025

April 2, 2025

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

September 19, 2024

Oropouche Virus Disease Among U.S. Travelers – United States, 2024

April 29, 2024

The subsidiary ProciseDx announces distribution agreement with Revvity’s EUROIMMUN US for the distribution of the ProciseDx platform in the United State and Canada

March 22, 2023

EUROIMMUN Wins 2023 New Jersey Top Workplaces Award

June 24, 2021

SARS-CoV-2 Variants of Concern (VOC) Alpha, Beta, Gamma and Delta

April 17, 2020

ABC News: Largest antibody study could answer crucial coronavirus questions

November 20, 2018

Membranous Nephropathy: Antibody-based diagnosis, prognosis, and disease monitoring

February 27, 2018

Measles and Mumps Forgotten Diseases of Recurring Relevance

July 27, 2017

Autoimmune Encephalitis – Anti NMDAR and Beyond

April 12, 2017

EUROIMMUN Announces Option Agreement with Roche on Zika Virus Serology

May 28, 2016

EUROIMMUN CEO Interviewed by Clinical Lab Products in regard to Zika virus

April 19, 2016

Zika Virus: Anatomy of a Global Health Crisis

February 17, 2016

First Commercial Serological Tests Available for Zika Virus Detection

2025 Euroimmun US

Euroimmun US Product Portfolio

Euroimmun US is one of the leading manufacturers worldwide and stands for innovation.

Autoimmune

Allergy

Antigen

Infection

Molecular genetic

Automation

For further product information, please visit our Euroimmun US products page

Euroimmun US: Certified
Great Place To Work^® 2024-2025

Where People Thrive Together in a Culture of Excellence!

Latest from Euroimmun US

Euroimmun Unveils New Visual Identity at ADLM 2025

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

Oropouche Virus Disease Among U.S. Travelers – United States, 2024

The subsidiary ProciseDx announces distribution agreement with Revvity’s EUROIMMUN US for the distribution of the ProciseDx platform in the United State and Canada

EUROIMMUN Wins 2023 New Jersey Top Workplaces Award

SARS-CoV-2 Variants of Concern (VOC) Alpha, Beta, Gamma and Delta

ABC News: Largest antibody study could answer crucial coronavirus questions

Membranous Nephropathy: Antibody-based diagnosis, prognosis, and disease monitoring

Measles and Mumps Forgotten Diseases of Recurring Relevance

Autoimmune Encephalitis – Anti NMDAR and Beyond

EUROIMMUN Announces Option Agreement with Roche on Zika Virus Serology

EUROIMMUN CEO Interviewed by Clinical Lab Products in regard to Zika virus

Zika Virus: Anatomy of a Global Health Crisis

First Commercial Serological Tests Available for Zika Virus Detection

Get in touch

Quick Links

Subscribe

Euroimmun US Product Portfolio

Euroimmun US is one of the leading manufacturers worldwide and stands for innovation.

For further product information, please visit our Euroimmun US products page

Euroimmun US: Certified Great Place To Work® 2024-2025

Where People Thrive Together in a Culture of Excellence!

Latest from Euroimmun US

Get in touch

Quick Links

Subscribe

Euroimmun US: Certified
Great Place To Work^® 2024-2025